Phoenix, AZ (PRWEB) May 27, 2016
Beacon Biomedical, Inc., a privately held company focused on developing highly accurate laboratory and point-of-care blood tests for colorectal cancer screening and early detection, announced today that it will be exhibiting at the BIO International Convention in San Francisco on June 6-9, 2016.
Beacon Biomedical will be featured in the Arizona Commerce Authority’s Arizona Pavilion at BIO 2016 located at booth #5322. Beacon has reached some significant milestones with its BeScreened™-CRC colorectal cancer screening test having demonstrated in its initial clinical data 95% accuracy across all patient demographics.
Dave English, Director of Business Development for Beacon Biomedical, commented, “We are excited to be part of BIO 2016 as a representative of the growing life sciences ecosystem of firms based in Arizona, and are looking forward to introducing ourselves to the global biotechnology community.”
About Beacon Biomedical, Inc.
Beacon Biomedical, Inc. is a privately held assay development and medical device company focused on developing and commercializing easy, accurate and affordable colorectal, breast and lung cancer screening solutions. Additional information about Beacon Biomedical is available at http://www.beaconbiomedical.com.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.